Diasorin heads to the US with $1.8bn Luminex deal

Diasorin heads to the US with $1.8bn Luminex deal

Source: 
EP Vantage
snippet: 

Yesterday’s debt-fuelled purchase of Luminex by Diasorin is, at $1.8bn, tied with Roche’s takeout of Genmark Diagnostics as the biggest acquisition of a Covid-19 test developer so far this year. But the buyers also have suites of Covid-19 assays of their own. Drowning in cash as a result, the big guns have their pick of acquisition targets to boost offerings and maintain market share even as demand – theoretically – wanes.